Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI

Contrast Media and Molecular Imaging

Volumn 6, Issue 4, 2011, Pages 209-218

  Faucher, Luc ^a,b   Guay Bégin, Andrée Anne ^a,b   Lagueux, Jean ^a   Côté, Marie France ^a   Petitclerc, Éric ^c   Fortin, Marc André ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c HÉMA QUÉBEC   (Canada)

Author keywords

Cell labeling; Cellular imaging; Cellular uptake; Chicken embryo; Gadolinium; Glioblastoma; Magnetic resonance imaging; Nanoparticles; Paramagnetic agents

Indexed keywords

GADOLINIUM; GADOLINIUM OXIDE; NANOPARTICLE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CANCER; CANCER CELL; CELL LABELING; CELL PROLIFERATION; CELL VIABILITY; CHORIOALLANTOIS; EMBRYO; GLIOBLASTOMA; IN VIVO STUDY; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CHICK EMBRYO; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES;

EID: 80051920726     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.420     Document Type: Article

References (53)

1. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 2006; 3: 554-562.
2. Heyn C, Ronald JA, Ramadan SS, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006; 56: 1001-1010.
3. Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 2003; 108: 1009-1014.
4. Bulte JW, Zhang S, van Gelderen P, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999; 96: 15256-15261.
5. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-414.
6. Ruehm SG, Corot C, Vogt P, Cristina H, Debatin JF. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 2002; 9: S143-S144.
7. Bottrill M, Nicholas LK, Long NJ. Lanthanides in magnetic resonance imaging. Chem Soc Rev 2006; 35: 557-571.
8. Merbach AE, Tôth E. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Wiley: Chichester, 2001.
9. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-2352.
10. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58: 1471-1504.
11. Heyn C, Ronald JA, Mackenzie LT, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006; 55: 23-29.
12. Muller RN, Vander Elst L, Roch A, et al. Relaxation by metal-containing nanosystems. Adv Inorg Chem Bioinorg Stud 2005; 57: 239-292.
13. Bulte JWM, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484-499.
14. Crich SG, Biancone L, Cantaluppi V, et al. Improved route for the visualization of stem cells labeled with a Gd-/Eu-chelate as dual (MRI and fluorescence) agent. Magn Reson Med 2004; 51: 938-944.
15. Nolte IS, Gungor S, Erber R, et al. In vitro labeling of glioma cells with gadofluorine M enhances T1 visibility without affecting glioma cell growth or motility. Magn Reson Med 2008; 59: 1014-1020.
16. Modo M, Mellodew K, Cash D, et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage 2004; 21: 311-317.
17. Vuu K, Xie JW, McDonald MA, et al. Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug Chem 2005; 16: 995-999.
18. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta(3) integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2103-2109.
19. Sirol M, Itskovich VV, Mani V, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004; 109: 2890-2896.
20. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004; 126: 16316-16317.
21. Bazzi R, Flores-Gonzalez MA, Louis C, et al. Synthesis and luminescent properties of sub-5-nm lanthanide oxides nanoparticles. J Luminesc 2003; 102: 445-450.
22. Söderlind F, Pedersen H, Petoral RM, Käll PO, Uvdal K. Synthesis and characterisation of Gd2O3 nanocrystals functionalised by organic acids. J Colloid Interface Sci 2005; 288: 140-148.
23. Park JY, Choi ES, Baek MJ, Lee GH, Woo S, Chang Y. Water-soluble ultra small paramagnetic or superparamagnetic metal oxide nanoparticles for molecular MR imaging. Eur J Inorg Chem 2009; 2477-2481.
24. Park JY, Baek MJ, Choi ES, et al. Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T-1 MR1 contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T-1 MR images. ACS Nano 2009; 3: 3663-3669.
25. Klasson A, Ahren M, Hällquist E, et al. Positive MRI contrast enhancement in THP-1 cells with Gd2O3 nanoparticles. Contrast Media Mol Imag 2008; 3: 106-111.
26. Abraham J, Gulley JL, Allegra CJ. Bethesda Handbook of Clinical Oncology, 2nd edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2005.
27. Sun C, Veiseh O, Gunn J, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008; 4: 372-379.
28. Martin AL, Bernas LM, Rutt BK, Foster PJ, Gillies ER. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines. Bioconjug Chem 2008; 19: 2375-2384.
29. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia 2001; 3: 489-499.
30. Nolte I, Vince GH, Maurer M, et al. Iron particles enhance visualization of experimental gliomas with high-resolution sonography. Am J Neuroradiol 2005; 26: 1469-1474.
31. Fortin MA, Petoral RM, Söderlind F, et al. Polyethylene glycol-covered ultra-small Gd2O3 nanoparticles for positive contrast at 1.5 T magnetic resonance clinical scanning. Nanotechnology 2007; 18. 395501 (1-9).
32. Pauling L, Shappell MD. The crystal structure of bixbyite and the C-modification of the sesquioxides. Z Kristallograph 1930; 75: 128-142.
33. Binns C. Nanoclusters deposited on surfaces. Surf Sci Rep 2001; 44: 1-49.
34. Engström M, Klasson A, Pedersen H, Vahlberg C, Käll PO, Uvdal K. High proton relaxivity for gadolinium oxide nanoparticles. Magma: Magn Reson Mater Phys Biol Med 2006; 19: 180-186.
35. Bridot JL, Faure AC, Laurent S, et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 2007; 129: 5076-5084.
36. Petoral RM, Söderlind F, Klasson A, et al. Synthesis and characterization of Tb3+-doped Gd2O3 nanocrystals: a bifunctional material with combined fluorescent labeling and MRI contrast agent properties. J Phys Chem C 2009; 113: 6913-6920.
37. Ahren M, Selegard L, Klasson A, et al. Synthesis and characterization of PEGylated Gd2O3 nanoparticles for MRI contrast enhancement. Langmuir 2010; 26: 5753-5762.
38. Faure AC, Dufort S, Josserand V, et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small 2009; 5: 2565-2575.
39. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724.
40. Fortin MA, Faucher L, Guay-Begin A, Petitclerc E. In vivo visualization of cells labeled with ultra-small Gd2O3 nanoparticles, using a 1.5 T clinical system and the chick embryo model. ISMRM 2009; Hawaii, 2009.
41. Roch A, Muller RN, Gillis P. Theory of proton relaxation induced by superparamagnetic particles. J Chem PhyS 1999; 110: 5403-5411.
42. De Stasio G, Casalbore P, Pallini R, et al. Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 2001; 61: 4272-4277.
43. Bridot JL, Dayde D, Riviere C, et al. Hybrid gadolinium oxide nanoparticles combining imaging and therapy. J Mater Chem 2009; 19: 2328-2335.
44. Szatmari T, Lumniczky K, Desaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97: 546-553.
45. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021.
46. Brooks PC, Montgomery AMP, Cheresh DA. Use of the 10-day old chick embryo model for studying angiogenesis. In Methods in Molecular Biology. Humana Press: Totowa, NJ, 1999; 257-269.
47. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276: 8135-8141.
48. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV - Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000; 275: 8051-8061.
49. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970; 30: 2394-2400.
50. Villeneuve J, Tremblay P, Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 2005; 65: 3928-3936.
51. Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Meth 1998; 213: 157-167.
52. Bain MM, Fagan AJ, Mullin JM, McNaught I, McLean J, Condon B. Noninvasive monitoring of chick development in ovo using a 7T MRI system from day 12 of incubation through to hatching. J Magn Reson Imag 2007; 26: 198-201.
53. Cabella, C. et al. Contrast Media Mol Imaging 2006; 1: 23-29.